Browse by Person

Export as [feed] Atom [feed] RSS
Group by: Item Type | No Grouping
Number of items: 24.

Article

Abani, O, Abbas, A, Abbas, F et al. (4809 more authors) (2021) Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. The Lancet, 397 (10289). pp. 2049-2059. ISSN 0140-6736

Abani, O orcid.org/0000-0003-2209-9956, Abbas, A, Abbas, F et al. (6346 more authors) (2021) Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet, 397 (10285). pp. 1637-1645. ISSN 0140-6736

Hafeez, S, Webster, A, Hansen, VN et al. (17 more authors) (2020) Protocol for tumour-focused dose-escalated adaptive radiotherapy for the radical treatment of bladder cancer in a multicentre phase II randomised controlled trial (RAIDER): radiotherapy planning and delivery guidance. BMJ Open, 10 (12). ARTN e041005. ISSN 2044-6055

Huddart, R, Hafeez, S, Lewis, R et al. (20 more authors) (2020) Clinical Outcomes of a Randomized Trial of Adaptive Plan-of-the-Day Treatment in Patients Receiving Ultra-hypofractionated Weekly Radiation Therapy for Bladder Cancer. International Journal of Radiation Oncology*Biology*Physics. ISSN 0360-3016

Syndikus, I, Cruickshank, C, Staffurth, J et al. (11 more authors) (2020) PIVOTALboost: A phase III randomised controlled trial of prostate and pelvis versus prostate alone radiotherapy with or without prostate boost (CRUK/16/018). Clinical and Translational Radiation Oncology. ISSN 2405-6308

Mostafid, AH, Porta, N, Cresswell, J et al. (14 more authors) (2020) CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin‐C vs surgical management in low‐risk non‐muscle‐invasive bladder cancer. BJU International, 125 (6). pp. 817-826. ISSN 1464-4096

Mateo, J, Porta, N, Bianchini, D et al. (38 more authors) (2020) Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. The Lancet Oncology, 21 (1). pp. 162-174. ISSN 1470-2045

Ofuya, M, McParland, L, Murray, L orcid.org/0000-0003-0658-6455 et al. (3 more authors) (2019) Systematic review of methodology used in clinical studies evaluating the benefits of proton beam therapy. Clinical and Translational Radiation Oncology, 19. pp. 17-26. ISSN 2405-6308

Thompson, MK, Poortmans, P, Chalmers, AJ et al. (6 more authors) (2018) Practice-changing radiation therapy trials for the treatment of cancer: where are we 150 years after the birth of Marie Curie? British Journal of Cancer, 119. pp. 389-407. ISSN 0007-0920

Jepson, M, Elliott, D, Conefrey, C et al. (104 more authors) (2018) An observational study showed that explaining randomization using gambling-related metaphors and computer-agency descriptions impeded randomized clinical trial recruitment. Journal of Clinical Epidemiology, 99. pp. 75-83. ISSN 0895-4356

Amos, R, Bulbeck, H, Burnet, NG et al. (9 more authors) (2018) Proton Beam Therapy – the Challenges of Delivering High-quality Evidence of Clinical Benefit. Clinical Oncology, 30. pp. 280-284. ISSN 0936-6555

Gopalakrishna, G, Langendam, M, Scholten, R et al. (470 more authors) (2017) Erratum to: Methods for evaluating medical tests and biomarkers. Diagnostic and Prognostic Research, 1 (11). pp. 2-5.

Harrington, K, Hall, E, Hawkins, M et al. (11 more authors) (2017) Introducing the Cancer Research UK Advanced Radiotherapy Technologies Network (ART-NET). Clinical Oncology, 29 (11). pp. 707-710. ISSN 0936-6555

Gopalakrishna, G, Langendam, M, Scholten, R et al. (468 more authors) (2017) Erratum to: Methods for evaluating medical tests and biomarkers. Diagnostic and Prognostic Research, 1. 11. ISSN 2397-7523

Sharma, RA, Plummer, R, Stock, JK et al. (36 more authors) (2016) Clinical development of new drug-radiotherapy combinations. Nature Reviews Clinical Oncology, 13 (10). pp. 627-642. ISSN 1759-4774

Mateo, J, Carreira, S, Sandhu, S et al. (48 more authors) (2015) DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. New England Journal of Medicine, 373 (18). pp. 1697-1708. ISSN 0028-4793

Bogaerts, J, Sydes, MR, Keat, N et al. (43 more authors) (2014) Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers Initiative. European journal of cancer. ISSN 0014-2964

Conference or Workshop Item

Huddart, R, Hafeez, S, Omar, A et al. (22 more authors) (2021) Acute toxicity of hypo- and conventionally-fractionated radiosensitised bladder radiotherapy. In: ESTRO 2021, 28-31 Aug 2021, Madrid, Spain & Online.

Huddart, RA, Lewis, R, Griffin, C et al. (17 more authors) (2020) Patterns of use of chemotherapy with radiotherapy in the treatment of muscle-invasive bladder cancer: Data from the RAIDER randomized trial of adaptive radiotherapy. In: 2020 Genitourinary Cancers Symposium, 13-15 Feb 2020, San Francisco, CA, USA.

Cruickshank, C, Mayles, H, Naismith, O et al. (8 more authors) (2019) Successful collaboration between a Clinical Trial Unit (CTU) and the National Radiotherapy Trials Quality Assurance (RTTQA) Group to expedite opening a complex phase III trial (PIVOTALboost). In: 5th International Clinical Trials Methodology Conference (ICTMC 2019), 06-09 Oct 2019, Brighton, UK.

Proceedings Paper

Huddart, R, Henry, A orcid.org/0000-0002-5379-6618, Staffurth, J et al. (16 more authors) (2018) OC-0058: Clinical outcomes of the first rct of adaptive radiotherapy in bladder cancer (HYBRID CRUK/12/055). In: Radiotherapy and Oncology. ESTRO 37, 20-24 Apr 2018, Barcelona, Spain. Elsevier , S25-S26.

Brown, S, Van Herk, M, Chuter, R et al. (18 more authors) (2018) Advanced Radiotherapy Technologies Network in the UK (ART-NET) - focus on lung cancer. In: Lung Cancer. 16th Annual British Thoracic Oncology Group Conference 2018, 24-26 Jan 2018, Dublin, Ireland. Elsevier , S60-S60.

Gopalakrishna, G, Langendam, M, Scholten, R et al. (468 more authors) (2017) Methods for Evaluating Medical Tests and Biomarkers. In: Diagnostic and Prognostic Research. Methods for evaluating medical tests and biomarkers: Symposium 2016, 19-20 Jul 2016, Birmingham, UK. BMC .

Sandhu, S, Mateo, J, Miranda, S et al. (31 more authors) (2015) Antitumour Activity of the Poly(Adp-Ribose) Polymerase (Parp) Inhibitor Olaparib in Unselected Sporadic Castration Resistant Prostate Cancer (Crpc) in the Toparp Trial. In: Asia-Pacific Journal of Clinical Oncology. ANZUP Annual Scientific Meeting: Redefining Personalised Medicine, 12-14 Jul 2015, Sydney, Australia. Wiley , pp. 28-29.

This list was generated on Sat Jan 1 20:59:52 2022 GMT.